Crossmark

Persistence and adverse events of biological treatment in adult patients with juvenile idiopathic arthritis: results from BIOBADASER

Crossref DOI link: https://doi.org/10.1186/s13075-018-1728-3

Published Online: 2018-10-10

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

,

Bethencourt Baute, Juan José

Sanchez-Piedra, Carlos

Ruiz-Montesinos, Dolores

Medrano San Ildefonso, Marta

Rodriguez-Lozano, Carlos

Perez-Pampin, Eva

Ortiz, Ana

Manrique, Sara

Roselló, Rosa

Hernandez, Victoria

Campos, Cristina

Sellas, Agustí

Sifuentes-Giraldo, Walter Alberto

García-González, Javier

Sanchez-Alonso, Fernando

Díaz-González, Federico

Gómez-Reino, Juan Jesús

Bustabad Reyes, Sagrario
Funding

Funding for this research was provided by:

Roche

Biogen

Bristol-Myers Squibb

Pfizer

Samsung Bioepis

Regeneron Pharmaceuticals

Novartis Pharmaceuticals Corporation

Janssen Pharmaceuticals

Celgene

Merck Sharp and Dohme
License Information

Text and Data Mining valid from 2018-10-10
More Information

Article History

Received: 16 March 2018

Accepted: 19 September 2018

First Online: 10 October 2018

Ethics approval and consent to participate

: The study was conducted in accordance with the principles of the Declaration of Helsinki. Ethics approval for the study was obtained from Hospital Clinic (Barcelona, Spain). The institutional review board at each participating center approved the protocol.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.